ACE and hydrops fetalis: The sodium–glucose co-transporter2 (SGLT2) inhibitors dapagliflozin and empagliflozin added to the triad (ACE-I/ARNI/beta blocker/MRA) lead to a reduction in the risk of CV death and worsening HF in patients with HFrEF [7,8].